TY - JOUR A1 - Schuhmacher, Alexander A1 - Gatto, Alexander A1 - Kuss, Michael A1 - Gassmann, Oliver A1 - Hinder, Markus T1 - Big Techs and startups in pharmaceutical R&D – A 2020 perspective on artificial intelligence JF - Drug Discovery Today UR - https://doi.org/10.1016/j.drudis.2021.04.028 Y1 - 2021 UR - https://doi.org/10.1016/j.drudis.2021.04.028 SN - 1878-5832 VL - 26 IS - 10 SP - 2226 EP - 2231 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Hinder, Markus A1 - Madesh, Nandhini A1 - Hartl, Dominik A1 - Schuhmacher, Alexander T1 - The Role of Data Monitoring Committees in drug research JF - Drug Discovery Today UR - https://doi.org/10.1016/j.drudis.2025.104474 Y1 - 2025 UR - https://doi.org/10.1016/j.drudis.2025.104474 SN - 1878-5832 VL - 30 IS - 10 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Schuhmacher, Alexander A1 - Gassmann, Oliver A1 - Kwisda, Sebastian A1 - Kremer, Malte A1 - Hinder, Markus A1 - Hartl, Dominik T1 - The R&D productivity challenge: transforming the pharmaceutical ecosystem JF - Drug Discovery Today N2 - The persistent decline in pharmaceutical R&D productivity has been extensively analyzed and debated for over two decades, with profound implications for the structure and strategy of the pharmaceutical industry. This systemic challenge forced many leading companies to adapt their R&D models, influencing internal capabilities and external innovation strategies. In response, the industry has evolved into a complex, interdependent biopharmaceutical ecosystem encompassing large pharmaceutical corporations, biotech innovators and specialized service providers. Although R&D productivity affects all research-driven companies, its consequences are particularly pronounced for large pharmaceutical firms, because the scale and capital intensity of their R&D activities make productivity a crucial determinant of long-term competitiveness and sustainability. By contrast, other stakeholders are only partially adversely affected, whereas some can even obtain value from it. UR - https://doi.org/10.1016/j.drudis.2025.104494 Y1 - 2025 UR - https://doi.org/10.1016/j.drudis.2025.104494 UR - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:573-64218 SN - 1878-5832 VL - 30 IS - 11 PB - Elsevier CY - Amsterdam ER - TY - CHAP A1 - Schuhmacher, Alexander A1 - Gassmann, Oliver A1 - Hinder, Markus ED - Schuhmacher, Alexander ED - Gassmann, Oliver ED - Hinder, Markus T1 - New Innovation Models in Pharmaceutical R&D T2 - Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation UR - https://doi.org/10.1002/9783527693405.ch18 Y1 - 2016 UR - https://doi.org/10.1002/9783527693405.ch18 SN - 978-3-527-69343-6 SN - 978-3-527-33913-6 SP - 401 EP - 415 PB - Wiley CY - Weinheim ER -